Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Assessing the Role of Exercise Intensity in Slowing Disease Progression in Early Parkinson’s Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2006 by Austin Health.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Austin Health
ClinicalTrials.gov Identifier:
NCT00385073
First received: October 5, 2006
Last updated: NA
Last verified: October 2006
History: No changes posted

October 5, 2006
October 5, 2006
April 2005
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Assessing the Role of Exercise Intensity in Slowing Disease Progression in Early Parkinson’s Disease
Assessing the Role of Exercise Intensity in Slowing Disease Progression in Early Parkinson’s Disease

Participants will complete a self-selected intensity of exercising over a 6 month period, with detailed clinical assessments at commencement and completion to determine the rate of progression of parkinsonism and gait abnormalities

Participants will complete a self-selected intensity of exercising over a 6 month period - including jogging, swimming and circuit training, with detailed clinical assessments at commencement and completion (including UPDRS, gaitrite lab study) to determine the rate of progression of parkinsonism and gait abnormalities

Observational
Observational Model: Defined Population
Time Perspective: Longitudinal
Not Provided
Not Provided
Not Provided
Not Provided
Parkinson's Disease
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
December 2007
Not Provided

Inclusion Criteria:

  • Early Parkinson's Disease,
  • Able to provide informed consent,
  • able to complete exercise diaries for 6 months,
  • no medications or on levo-dopa

Exclusion Criteria:

  • Not on dopamine agonists,
Both
Not Provided
No
Contact: mary m Galea, PhD 0061383444171 ext nil m.galea@unimelb.edu.au
Australia
 
NCT00385073
126/05
Not Provided
Not Provided
Austin Health
Not Provided
Principal Investigator: mary m galea, PgD Austin Health
Austin Health
October 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP